Meeting
2022 ASCO Annual Meeting
Plasma first: Accelerating lung cancer diagnosis through liquid biopsy.
Authors
Miguel Garcia Pardo
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Miguel Garcia Pardo , Kasia Czarnecka , Jennifer H. Law , Alexandra Maria Salvarrey , Roxanne Fernandes , Jason Fan , Lucy Corke , Lisa W Le , Thomas K. Waddell , Kazuhiro Yasufuku , Geoffrey Liu , Frances A. Shepherd , Penelope Ann Bradbury , Adrian G. Sacher , Tracy Stockley , Prodipto Pal , Ming Sound Tsao , Karen Howarth , Christodoulos Pipinikas , Natasha B. Leighl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Clinical Trial Registration Number
NCT04863924
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3039)
DOI
10.1200/JCO.2022.40.16_suppl.3039
Abstract #
3039
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).
First Author: Christian Diego Rolfo
Poster
2023 ASCO Annual Meeting
Relevance and accuracy of ChatGPT-generated NGS reports with treatment recommendations for oncogene-driven NSCLC.
First Author: Zac Hamilton
Poster
2018 ASCO Annual Meeting
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
First Author: Laura Mezquita
Poster
2017 ASCO Annual Meeting
Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting.
First Author: Jordi Remon